Causes of Visual Loss in Retinal Disease

This study is enrolling participants by invitation only.
Sponsor:
Information provided by (Responsible Party):
Simon Taylor, Royal Surrey County Hospital
ClinicalTrials.gov Identifier:
NCT01613963
First received: May 29, 2012
Last updated: June 5, 2012
Last verified: June 2012

May 29, 2012
June 5, 2012
May 2012
December 2012   (final data collection date for primary outcome measure)
Visual acuity at 5 years [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Best-corrected visual acuity at 5 years
Same as current
Complete list of historical versions of study NCT01613963 on ClinicalTrials.gov Archive Site
  • Visual acuity at 10 years [ Time Frame: 10 years ] [ Designated as safety issue: No ]
    Best corrected visual acuity at 10 years
  • Source of referral [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Categorised as A&E/GP referral/Optician referral/Tertiary referral
  • Laterality [ Time Frame: Baseline ] [ Designated as safety issue: No ]

    Categorised as:

    Right eye/Left eye/Bilateral

  • Anatomical diagnosis [ Time Frame: Baseline ] [ Designated as safety issue: No ]

    Cateogorised as:

    Acute anterior uveitis / Chronic anterior uveitis / Fuchs heterochromic cyclitis / Intermediate uveitis / Pars planitis / Posterior Uveitis / Panuveitis / Episcleritis / Scleritis

  • Aetiological diagnosis [ Time Frame: Baseline ] [ Designated as safety issue: No ]

    Diagnosed as:

    Viral / Bacterial / Fungal / Parasitic / Inflammatory / Malignant

  • Associated systemic disease [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Any associated systemic disease, e.g. HLA-B27 associated disease, Behcet's disease, multiple sclerosis, Vogt-Koyanagi-Harada syndrome, rheumatoid arthritis, collagen vascular disease, tuberculosis, granulomatosis with polyangiitis
  • Complications of disease and causes of visual loss at 5 years [ Time Frame: 5 years ] [ Designated as safety issue: No ]

    Categorised into:

    Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other

  • Complications of disease and causes of visual loss at 10 years [ Time Frame: 10 years ] [ Designated as safety issue: No ]

    Categorised into:

    Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other

  • Complications of disease and causes of visual loss [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

    Categorised into:

    Corneal clarity problems / cataract / vitreous debris / retinal detachment / cystoid macular edema / retinal pigment epithelium atrophy / macular scarring / epiretinal membrane / macular hole / steroid response / glaucoma / other optic neuropathy / hypotony & phthisis / other

  • Treatment measures employed [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

    Categorised into:

    Topical treatment / periocular steroid / intraocular steroid / intraocular other agent / Glaucoma treatment / systemic immunosuppressive agents

  • Complications of disease and treatment [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]

    Categorised into:

    1. Local complications: Raised intraocular pressure / cataract / endophthalmitis / other
    2. Systemic complications: Diabetes / hypertension / cholesterol / liver function / bone density loss / other
  • Surgical procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    List and dates of any intraocular surgery performed during the study
  • Burden of disease - appointments [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Number of outpatient appointments over the course of the study
  • Burden of disease - outpatient procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Number of outpatient procedures over the course of the study
  • Burden of disease - inpatient procedures [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Number of inpatient procedures over the course of the study
  • Blind registration [ Time Frame: Up to 10 years ] [ Designated as safety issue: No ]
    Year of any registration as partially sighted or blind
Same as current
Not Provided
Not Provided
 
Causes of Visual Loss in Retinal Disease
Observational Study of Visual Outcomes in Retinal Disease

This is a study of visual outcomes in retinal disease that seeks to identify the causes of visual loss. This data will be used to predict which patients are at risk of losing vision and how they can be better treated.

This is a study of visual outcomes in retinal disease. It is an observational study of patients who have been seen in the retinal clinic, and involves a retrospective casenotes analysis to identify patients who have suffered visual loss and the reason for that visual loss. These data will be analysed to enable the identification of factors that predict visual loss in patients who present earlier in the course of their disease.

Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients with ocular inflammation

  • Uveitis
  • Scleritis
Drug: Immunosuppressive Agents
Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
Other Names:
  • Prednisolone
  • Azathioprine
  • Methotrexate
  • Mycophenolate mofetil
  • Cyclosporine A
  • Infliximab
  • Adalimumab
  • Etanercept
  • Rituximab
Patients with ocular inflammation
Patients with ocular inflammation
Intervention: Drug: Immunosuppressive Agents
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Enrolling by invitation
2000
December 2012
December 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients with a diagnosis of ocular inflammation
  • patients with at least 6 months of follow-up

Exclusion Criteria:

  • patients without a diagnosis of ocular inflammation
  • patients with less than 6 months of follow-up
Both
16 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
NCT01613963
12DEV0010
No
Simon Taylor, Royal Surrey County Hospital
Royal Surrey County Hospital
Not Provided
Principal Investigator: Simon RJ Taylor, PhD FRCOphth Royal Surrey County Hospital
Royal Surrey County Hospital
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP